Skip to content
ULDULDULD

Drawing based on the label description. No photo yet.

“Widaplik tablets are available as follows: 10 mg/1.25 mg/0.625 mg: 10 mg telmisartan/1.25 mg amlodipine/0.625 mg indapamide tablets - white to off-white oval tablet, debossed with "ULD" on one side and plain on the other side”

ULD pill

Pill with imprint ULD is white, oval, 13 mm and has been identified as Telmisartan, Amlodipine and Indapamide 10 mg / 1.25 mg / 0.625 mg. It is used for high blood pressure. It is supplied by Azurity Pharmaceuticals, Inc.

Telmisartan, Amlodipine and Indapamide 10 mg / 1.25 mg / 0.625 mg

Imprint
ULD
Strength
Telmisartan 10 mg / Amlodipine 1.25 mg / Indapamide 0.625 mg
Used for
High blood pressure
Color
White
Shape
Oval
Size
13 mm
Score
No score line
Form
Tablet
Manufacturer
Azurity Pharmaceuticals, Inc
Drug class
ARB (blood pressure medicine)
NDC
24338-001, 24338-001-30

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Telmisartan, Amlodipine and Indapamide pills and guides

What is Telmisartan, Amlodipine and Indapamide used for?

Telmisartan, Amlodipine and Indapamide is used for high blood pressure.

Medicine type
ARB (blood pressure medicine); calcium channel blocker (blood pressure and heart medicine)
Official uses from the US prescribing label

Widaplik (telmisartan/amlodipine/indapamide) is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Widaplik may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers, dihydropyridine calcium channel blockers and thiazide-like diuretics. There are no controlled trials demonstrating risk reduction with Widaplik.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, the target goal, and the incremental likelihood of achieving the goal with a triple combination product compared with mono- or dual therapy when deciding whether to use Widaplik as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk.

From the FDA-approved label on DailyMed (published Jul 13, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows ULD and the other side is plain.
  • It is white, oval, 13 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold under the brand name Widaplik.

Ingredients

Active: Telmisartan, Amlodipine Besylate, Indapamide

Inactive: Microcrystalline Cellulose 101, Mannitol, Sodium Hydroxide, Povidone, Meglumine, Croscarmellose Sodium, Magnesium Stearate, Starch, Corn

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Telmisartan, Amlodipine and Indapamide pills